Risk of Readmission for Wheezing during Infancy in Children with Congenital Diaphragmatic Hernia

Gregoire Benoist1, Mostafa Mokhtari2, Antoine Deschildre3

  • 1Pneumologie Pédiatrique, Necker, AP-HP, Paris, France, Centre de Référence des Maladies Respiratoires Rares, Paris, France.

Plos One
|May 13, 2016
PubMed

Insights

Infants with congenital diaphragmatic hernia (CDH) have frequent respiratory issues and high readmission rates for wheezing. Several factors influence these readmissions, but palivizumab did not reduce them.

Area of Science:

  • Pediatric Pulmonology
  • Neonatal Surgery
  • Clinical Epidemiology

Background:

  • Congenital diaphragmatic hernia (CDH) is linked to significant respiratory morbidity post-discharge.
  • The frequency of infant re-hospitalization for respiratory issues in CDH patients is not well-established.

Purpose of the Study:

  • To determine the readmission rate for wheezing in infants with CDH up to 24 months of age.
  • To identify risk factors associated with wheezing-related readmissions in this population.

Main Methods:

  • A prospective national database analysis of infants with CDH born in French tertiary centers (2009-2013).
  • Inclusion criteria: infants alive at discharge; data extraction for wheezing episodes and readmissions up to 24 months.
  • Statistical analysis to identify factors associated with readmission.

Main Results:

  • 26% of 86 infants with CDH were readmitted for wheezing exacerbations before 24 months.
  • Factors associated with readmission included thoracic liver herniation, low gestational age, prolonged initial hospitalization, home oxygen use, and eczema.
  • Respiratory Syncytial Virus (RSV) was detected in 40% of first readmissions with available samples.
  • Palivizumab prophylaxis did not correlate with reduced readmission rates or RSV hospitalizations.

Conclusions:

  • Infants with CDH experience a high rate of readmission for wheezing exacerbations.
  • Prenatal and neonatal factors significantly influence readmission risk.
  • Palivizumab prophylaxis showed no impact on reducing wheezing-related readmissions in this cohort.
Abstract

Related Concept Videos

Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
4.7K
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
1.4K
Assessment of Respiration01:23

Assessment of Respiration

The respiratory system's basic structures and primary functions lay the foundation for nurses' comprehensive respiratory assessments. This assessment includes subjective and objective data to gauge the patient's respiratory health.
Subjective Assessment: Nurses interview the patient to gather information directly during the subjective assessment. It includes questions about the individual's medical history, medications, and symptoms, focusing on past respiratory conditions like...
2.3K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.5K
Endoscopic Studies II: Thoracocentesis01:26

Endoscopic Studies II: Thoracocentesis

Thoracentesis(Thoracocentesis), commonly known as pleural tap, is a medical procedure where a 22 gauge needle is inserted into the pleural space, the area between the lung and chest wall. This procedure is commonly performed to diagnose or treat various respiratory disorders.
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
1.9K
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
1.1K